RT Journal Article
SR Electronic
A1 Parry, Nicola
T1 Empagliflozin Superior to Glimepiride as Second-line Treatment in T2DM
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 32
SP 12
OP 13
DO 10.1177/155989771432006
UL http://mdc.sagepub.com/content/14/32/12.abstract
AB Empagliflozin is superior to glimepiride as an add-on treatment option for patients with type 2 diabetes mellitus who have not achieved good glycemic control on metformin, according to results from the Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes trial that are presented in this article.